glp 1 blindness study GLP-1 Agonists—commonly used for weight loss and diabetes—are now being linked to serious eye health concerns, including an increased risk of a condition called NAION, which can cause irreversible blindness. With GLP-1 Sight Unseen: Glucagon-Like Peptide-1 (GLP-1)

For anti-obesity drugs to be widely adopted, they must not only demonstrate clinical efficacy but also provide a favorable costbenefit ratio compared to existing treatments

This may be of clinical significance especially for medications with a narrow therapeutic index, where small differences in blood concentration might lead to therapeutic failure or adverse reactions

2021;131 doi: 10.1172/JCI151800

doi: 10.1097/XCS.0000000000000325

Advertencia a comercios y distribuidores El ISP record que fabricar, importar, distribuir o publicitar estos productos constituye una infraccin sanitaria

Because these medications act on the bodys natural systems, they may also offer benefits beyond weight loss, such as supporting healthy blood sugar regulation